ORLANDO, Fla. — Clinical trials in multiple myeloma continue to rapidly progress, and nowhere was this more apparent than at the American Society of Hematology’s annual meeting. Companies like Johnson & Johnson, Gilead and Arcellx were …
UK confirms lower clawback rate for NHS medicines
The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is “only